X4 Pharmaceuticals, Inc — Director's Dealing 2020

Dec 1, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: X4 Pharmaceuticals, Inc (XFOR)
CIK: 0001501697
Period of Report: 2020-11-30

Reporting Person: Taveras Arthur (Chief Scientific Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-11-30	Stock Option (right to buy)	$6.6	A	121150	Acquired	2030-11-29	Common Stock (121150.0)	Direct

Footnotes

F1: 25% of the shares subject tot he option shall vest on November 30, 2021, with the remainder vesting in equal installments of 2.0833% of the shares subject to the option each successive month thereafter for a period of 36 months, subject to the Reporting Person continuing to provide services through each such date.